Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive
NCT ID: NCT03296098
Last Updated: 2025-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2020-12-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days
NCT01953679
Impact of Combined Hormonal Contraceptives on UPA
NCT02577601
A proof-of Concept, Randomized 3-month Study to Evaluate the Effects of Three Contraceptive Intrauterine Systems Delivering Copper and a Daily Dose of 5, 20 or 40 μg of Ulipristal Acetate (UPA)
NCT03230539
On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility
NCT03354117
Ovarian Function With ENG Implant and UPA Use
NCT04291001
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ulipristal acetate
Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
Ulipristal acetate
Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ulipristal acetate
Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Be in good general overall health with no chronic medical conditions that result in periodic exacerbations that require significant medical care.
2. Be women between 18 and 35 years inclusive at the enrollment visit.
3. Have regular menstrual cycles that occur every 21-35 days when not using hormonal contraception.
a. If subject is postpartum or post-abortal, she must have one menstrual bleed prior to enrollment.
4. Be seeking contraception, and willing to use the study drug as the only contraception method during their months of study participation.
5. If using a ring, patch, pill, or implant prior to study treatment, the subject must discontinue the active hormone at least 4 days, and no more than 7 days, prior to study drug initiation. Note that for combined oral contraceptive users, placebo pills are not counted as active hormone.
6. If using a hormonal intrauterine device (IUD) prior to study treatment, the IUD must be removed prior to study drug initiation; removal and study drug initiation can occur on the same day, but the subject must refrain from sexual intercourse for 7 days following IUD removal.
7. If using a copper IUD prior to study treatment, the IUD must be removed prior to study drug initiation; removal and study drug initiation can occur on the same day. The IUD removal and study drug initiation must occur during the first 7 days of a spontaneous menses.
8. If using a non-hormonal contraceptive method (e.g. condoms or withdrawal) prior to study treatment, drug initiation should occur within the first 7 days of a spontaneous menses.
9. If the woman has received a long-acting injectable contraceptive (e.g. depomedroxyprogesterone acetate) during the 10 months prior to screening, she must have resumed cyclic spontaneous menses (two menstrual bleeds) since last injection.
10. Have a negative urine pregnancy test at the enrollment visit.
11. Have an intact uterus and both ovaries.
12. In the opinion of the investigator, be willing and able to follow all study requirements, including use of the study product and be willing to record requested information on a daily diary.
13. Understand and sign an (Institutional Review Board) IRB approved informed consent form prior to screening activities (including fasting blood draws).
14. Have a diastolic blood pressure (BP) ≤95 mm Hg and systolic BP ≤145 mm Hg after 5 minutes in a sitting position at the enrollment visit. Hypertensive subjects who are treatment controlled and, in the judgment of the investigator, are good candidates require a waiver for participation.
15. Have a body mass index (BMI) \< 40 kg/m2.
16. Be planning to have at least one act of heterosexual vaginal intercourse each month during study participation.
17. Be willing to accept an unknown risk of pregnancy during study participation.
Exclusion Criteria
1. Be women with irregular menstrual cycles defined as a variation in cycle length of more than 5 days.
2. Be planning pregnancy within their months of study participation.
3. Be currently breast-feeding or within 30 days of discontinuing breast feeding, unless the subject has already had a menses following discontinuation of breast feeding.
4. Have undiagnosed abnormal genital bleeding.
5. Have known hypersensitivity to the active substance UPA or any of the excipients of the study treatment.
6. Have a history of endometrial hyperplasia or malignancy.
7. Have abnormal Transvaginal Ultrasound (TVUS) or safety labs done at the screening visit recognized as clinically significant by the investigator (or medically qualified designee).
8. Have a previous history of endometrial ablation.
9. Have a previous history of liver disease or screening liver enzyme results more than three times the upper limit of normal values.
10. Have a known clinically significant Pap test abnormality, as managed by current local or national guidelines, that would require treatment during study participation.
11. Have any of the following known contraindication to progestin-only oral contraceptive (OC):
1. History or existing breast cancer, or other hormone sensitive neoplasia;
2. Current or history of ischemic heart disease or stroke while pregnant or taking birth control pills;
3. Systemic Lupus Erythematosus with positive or unknown antiphospholipid antibodies;
4. Benign or malignant liver tumors;
5. Severe (decompensated) cirrhosis.
12. Have known or suspected alcoholism or drug abuse.
13. Have known HIV infection.
14. Have an anticipated need for regular condom use as defined as use of at least one condom per month after enrollment.
15. Have previously participated in the study.
16. Have a current need for exogenous hormones or therapeutic anticoagulants.
17. Have a current or history of deep vein thromboembolic disorder or aortic thromboembolism, including stroke and myocardial infarction
18. Have a current or past medically diagnosed severe depression, which, in the opinion of the investigator, could be exacerbated by use of a hormonal contraceptive, unless she is stable on antidepressant medication.
19. Have concomitant use of medication thought to interact with UPA (per Summary of Product Characteristics (SPCs)) such as CYP3A4 inducers (rifampin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, phenytoin, St John's Wort, topiramate).
20. Have concomitant use of moderate or strong CYP3A4 inhibitors as identified by the FDA. Subjects who begin use of a moderate CYP3A4 inhibitor after study enrollment require a waiver to continue in the study.
21. Use any medications that can interfere with the metabolism of hormonal contraceptives, antibiotics that can interfere with metabolism of hormonal contraceptives, or any drugs designated by the FDA as falling in the Pregnancy and Lactation narrative subsections (formerly Category D or X medications).
22. Currently participate in any other trial of an investigational medicine or device or have participated in the three months before start of treatment or be planning to participate in another clinical trial during this study.
23. Have a history of a bariatric surgery procedure associated with malabsorption.
24. Be planning to undergo major surgery during study participation.
25. Live outside of the catchment area of the study site.
26. Have used UPA, including Ella, within 30 days prior to enrollment and not had a menses since using UPA.
27. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities.
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Premier Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Essential Access
Los Angeles, California, United States
University of California, Davis
Sacramento, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Colorado
Denver, Colorado, United States
University of Hawaii
Honolulu, Hawaii, United States
University of Chicago
Chicago, Illinois, United States
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States
New York University, School of Medicine
New York, New York, United States
Columbia University
New York, New York, United States
University of Cincinnati
Cincinnati, Ohio, United States
University Hospitals of Cleveland MacDonald Women's Hospital
Cleveland, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Univeristy of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
University of Utah
Salt Lake City, Utah, United States
Eastern Virginia Medical School (EVMS)
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCN013B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.